LeonaBio, Inc. Common Stock (LONA) is a publicly traded the market company. As of May 21, 2026, LONA trades at $11.53 with a market cap of $95.16M and a P/E ratio of 0.00. LONA moved -6.54% today. Year to date, LONA is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $4.21 to $14.21. Analyst consensus is buy with an average price target of $16.00. Rallies surfaces LONA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
LeonaBio Appoints Callori, Holles and Silverman to Strengthen Clinical Pipeline Strategy: LeonaBio appointed Fred Callori, Natalie Holles and Peter B. Silverman to its Board effective May 5, 2026, replacing retiring director John Fluke Jr. after his decade-long tenure. The additions bring extensive oncology and neurology drug development, corporate strategy and capital markets expertise to support advancement of LeonaBio’s clinical-stage pipeline.
| Metric | Value |
|---|---|
| Price | $11.53 |
| Market Cap | $95.16M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.21 |
| 52-Week Low | $4.21 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
2 analysts cover LONA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.00.